Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective

Published:2020-07-07 Issue: Volume:11 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Guo Libin,Wei Ran,Lin Yao,Kwok Hang Fai

Funder

Fundo para o Desenvolvimento das Ciências e da Tecnologia

Ministry of Science and Technology of the People's Republic of China

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference194 articles.

1. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes;Agata;Int Immunol.,1996

2. Functional expression of programmed death-ligand 1 (B7-H1) by immune cells and tumor cells;Gibbons;Front Immunol.,2017

3. Interferon gamma in cancer immunotherapy;Ni;Cancer Med.,2018

4. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer;Granier;Esmo Open.,2017

5. PD-1 signaling in primary T cells;Riley;Immunol Rev.,2009

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and immunotherapy efficacy of a PD-L1 small-molecule inhibitor combined with its 131I-iodide labelled isostructural compound;Bioorganic Chemistry;2024-12

2. Parthenolide Inhibits Synthesis and Promotes Degradation of Programmed Cell Death Ligand 1 and Enhances T Cell Tumor-Killing Activity;Journal of Agricultural and Food Chemistry;2024-09-12

3. Efficacy and Safety of Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Antibodies Plus Chemotherapy as First-Line Treatment for NSCLC in the People’s Republic of China: a Systematic Review and Meta-Analysis;JTO Clinical and Research Reports;2024-06

4. Tumor cells inhibit the activation of ILC2s through up-regulating PD-1 expression;Immunopharmacology and Immunotoxicology;2024-05-03

5. Bending the Rules: Amplifying PD-L1 Immunoregulatory Function Through Flexible Polyethylene Glycol Synthetic Linkers;Tissue Engineering Part A;2024-04-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3